StockData

Amneal Pharmaceuticals vs Elanco Animal Health

AMRX and ELAN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMRX and ELAN compare

Elanco Animal Health is the larger company, worth 1.9 times as much as Amneal Pharmaceuticals ($13.2B against $6.8B).

Elanco Animal Health grew revenue faster over the last twelve months (12.0% versus 9.3% for Amneal Pharmaceuticals).

Amneal Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 5.0% compared with −4.0% at Elanco Animal Health.

Amneal Pharmaceuticals scores higher on the StockData Score (10 against 9 for Elanco Animal Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMRXELAN
Size and price
Market cap$6.8B$13.2B
Share price$21.23$26.41
Change, 1 year84.3%20.1%
Change, 5 years400%−12.6%
Beta (5Y)0.900.09
Employees8,5009,400
StockData Score
Total score10 (better)9
Valuation score01 (better)
Growth score5 (better)3
Performance score4 (better)3
Health score12 (better)
Dividend score00
Valuation
P/E43.3×–
P/S2.2× (better)2.6×
P/B205×2.0× (better)
EV/EBITDA20.3× (better)31.5×
P/FCF53.0×34.8× (better)
FCF yield1.9%2.9% (better)
Fair value$13.07$11.30
Margin of safety−62.4% (better)−134%
Growth
Revenue growth (TTM)9.3%12.0% (better)
Revenue growth, 5Y average8.7% (better)7.6%
Net income growth (TTM)4563% (better)−146%
EPS growth (TTM)4800% (better)−149%
EPS growth, 5Y average−18.5%–
Profitability
Gross margin39.3%55.4% (better)
Operating margin14.6%–
Net margin5.0% (better)−4.0%
FCF margin4.1%7.5% (better)
Return on equity–−3.0%
Return on invested capital20.3%–
Financial health
Debt / equity77.830.59 (better)
Net debt / EBITDA5.38 (better)6.43
Current ratio2.20 (better)2.05
Altman Z-score2.49 (better)1.46
Piotroski F-score7 (better)6
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions52.7%113%
Held by insiders60.7%1.1%
Insider net buying, 12 months−$7.7M$2.5M (better)
Short interest, % of float9.1%6.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.